Tag Archives: CTAC

Access to Hep C Treatment in Federal Institutions Webinar

Access to Hep C Treatment in Federal Institutions WebinarThursday, March 23rd at 11am PST,  join CTAC Policy Researcher Amanda Fletcher’s webinar to learn more about the prevalence of hepatitis C in Canada’s federal institutions.*

Hepatitis C impacts between 250,000-300,000 Canadians, among whom at least 44% are undiagnosed and untreated. While the national hep C burden among Canadians is approximately 1%, the prevalence of hep C in correctional institutions is estimated to be between 20 and 40%.

March 23rd CTAC Webinar

This CTAC webinar will focus on issues and recommendations around access to hep C treatment in federal institutions and address questions like: How has treatment, traditionally, been administered? What are the factors behind such a high hep C prevalence rate? What kind of preventative measures can be taken? How have Correctional Service Canada’s drug eligibility restrictions changed, and what does this mean for hep C treatment within the institutional setting?

Learn more about screening; treatment; harm reduction; social determinanents of health (gender, mental health/substance abuse); Correctional Service Canada’s new and less restrictive eligibility requirements around fibrosis scores; and, finally, CTAC’s recommendations for increasing treatment access.

Don’t delay. Register now!

On the day of the event, you will need to log on to the webinar at http://ctac.adobeconnect.com/hepCprison and dial in for the audio toll-free at 877-473-4906 with conference code 4564615148

CTAC

CTAC is an organization that focuses on access to treatment for people living with HIV and HIV/HCV co-infection. Since 1996, they have worked to secure and ensure equitable, affordable and timely access to treatment, care and support for people in Canada living with HIV and HIV/HCV co-infection.
*Content by CTAC

Strategies to Address Reimbursement Restrictions

Strategies to address reimbursement restrictionsClick here to view a recording of the February 6th webinar Strategies to address reimbursement restrictions for Hep C treatment: Lessons from Australia.

In collaboration with CanHepC, CTAC, and The Kirby Institute in Australia, CATIE organized this webinar to look at strategies to address Canada’s current restrictive and inconsistent approach to direct-acting antiviral (DAA) access and the lessons we can learn from the Australian model.

Learn from experts like Alison Marshall and Greg Dore of Australia’s The Kirby Institute; and Helen Tyrell of Hepatitis Australia. Listen to a discussion between Adam Cook of CTAC and Action Hepatitis Canada’s Community Organizer, Zoe Dodd.

 

Treatment Access Webinar February 6th at 12-1:30pm

Treatment Access Webinar February 6th at 12-1:30pmClick here for more information and to register for the webinar on February 6th at 12-1:30pm PST.

In collaboration with CanHepC, CTAC, and the Kirby Institute in Australia, CATIE is organizing a webinar looking at strategies to address Canada’s current restrictive and inconsistent approach to direct-acting antiviral (DAA) access and lessons we can learn from the Australian model.

Register now and learn from experts such as Alison Marshall and Greg Dore of Australia’s The Kirby Institute; and Helen Tyrell of Hepatitis Australia. Engage in discussion with Adam Cook of CTAC and Action Hepatitis Canada; Community Organizer Zoe Dodd.

Sofosbuvir/Velpatasvir CTAC Webinar

Sofosbuvir/Velpatasvir CTAC Patient Group Input WebinarThis Monday, May 2nd, from 11 AM to 12 PM (PDT/in BC) / 2 PM to 3 PM (EDT/in Ontario), the Canadian Treatment Action Council (CTAC) will be hosting a webinar about the exciting new hep C treatment sofosbuvir/velpatasvir.

Following the webinar, there will be a survey to collect information that will help them write a patient input report for sofosbuvir/velpatasvir’s Common Drug Review. CTAC’s sofosbuvir/velpatasvir survey is different from PHCN’s patient input survey or PHCN’s loved ones/caregivers survey. Please consider filling out the still available PHCN survey that was created for you as well as CTAC’s survey.

Registration for the CTAC webinar is required to attend
. Click here to register and for more information about the webinar.

The Canadian Treatment Action Council (CTAC)

CTAC is a Canadian non-governmental organization led by and for people living with HIV and HIV/HCV co-infection. Since 1996, they have been working to secure and ensure equitable, affordable, and timely access to treatment and care and support for people in Canada living with HIV and HIV/HCV co-infection.

Patient Group Input Reports Requested by CADTH’s Common Drug Reviews

Within the Canadian drug approval process, Health Canada first evaluates a drug’s safety, clinical effectiveness, and its manufacturing process. The Common Drug Review (CDR) by CADTH then assesses the treatment’s clinical and cost-effectiveness as it compares to other treatments.

During Common Drug Reviews, CADTH requests patient input reports. These patient input reports help ensure that health outcomes and issues important to patients are incorporated into the Common Drug Review process in a formal and meaningful way.

 Sofosbuvir/Velpatasvir

Sofosbuvir/velpatasvir is an all-pill, short-course (sometimes only 8 weeks), interferon-free treatment that can be taken with or without ribavirin. In Phase 3 clinical trials, sofosbuvir/velpatasvir (with or without ribavirin) cured an overall 99% of those with genotype 1, 2, 4, 5, or 6 hep C and was found to be well tolerated by patients.

“This drug regimen changes the standard of care in treating patients with HCV. We can now cure almost everyone with a very simple treatment,” said Dr. Jordan Feld, a liver specialist at Toronto Western Hospital.

Highlights of a Hep C Advocate’s 2015

Highlights of a Hep C Advocate’s 2015Hep C advocates are essential to bettering the lives of those living with hep C. As we are just about to ring in 2016, the Hepatitis C Treatment Information Project wanted to look back and highlight some of the 2015 work of one of our hep C advocates.

The following is a collection of 2015 articles, events, and resources that Daryl Luster, hep C advocate and president of PHCN, was a part of:

February 5 – 6 — Toronto, Ontario

Advocacy training and advisory board meetings with representatives from the Canadian Liver Foundation, Hemophilia Society, Canadian Treatment Action Council (CTAC), Action Hepatitis Canada (AHC), HepCBC, as well as other groups from across Canada.

February 10 — Toronto, Ontario
AHC Steering Committee Meeting

Daryl is part of AHC‘s executive. AHC is a group that unites organizations and individuals to focus increased attention on the response to hepatitis B and C.

February 11 – 12 — Toronto, Ontario
A meeting entitled ‘National Deliberative Dialogue on Integrated HCV Programming and Services‘ with CATIE
As part of day two discussions, ‘Addressing Different Realities and Priorities: A Population-Level Discussion’, Daryl presented on the older adult population and participated in a panel discussion.

February 24 — Richmond, British Columbia

A meeting with representatives from UBC’s Faculty of Science regarding PHCN‘s participation in supporting research that impacts the hep C community. Daryl shared his own hep C experience and that of people in the community.

February 24 – 26 — Richmond, British Columbia

PHCN participated in a conference entitled ‘Frontline Support Workers’ Conference‘ put on by Pacific AIDS Network and CATIE.

February 26 – March 1 — Banff, Alberta

AHC‘s executive meeting and CATIE‘s learning institute meetings
The objective of these meetings was to identify key messages and information from a symposium on hep C. Daryl presented on the meeting’s last day.

February 27 — Banff, Alberta

4th Canadian Symposium on HCV
Symposium theme: ‘Strategies to Manage HCV Infection in Canada: Moving Towards a National Action Plan’. Daryl presented in his roles with AHC and PHCN. His talk was entitled ‘The role for Patient Advocacy in building a Canadian HCV action plan‘.

March 12 — Penticton, British Columbia

Penticton’s Healthy Living Fair
Working alongside Kathryn (RN), the Penticton & District Community Resources Society (PDCRS) outreach person for hep C related issues and harm reduction in the district, Daryl spoke to fair attendees and handed out literature about hep C screening and treatment access.

March 23

Daryl was quoted by BC’s Ministry of Health in their news release about Sovaldi and Harvoni.

March 24

Daryl was quoted by The Vancouver Sun and The National Post.

April 2 — Vancouver, British Columbia

Daryl had a letter published by The Vancouver Sun about hepatitis C in BC and the importance of treatment access.

April 14 — Vancouver, British Columbia

Pacific Blue Cross Workplace Health Symposium
Daryl presented with Alnoor Ramji MD FRCP(C), Clinical Associate Professor, Division of Gastroenterology, UBC. They spoke on hep C treatment and management to help employers better understand how to support employees and the benefits new treatment options may offer.

May 7 – 8 — Vancouver, British Columbia

First Nations Health Authority’s Gathering Wisdom VII event

May 9 — Richmond, British Columbia

Daryl presented and participated in a panel discussion at the Richmond Centre for Disability‘s Invisible Illness Awareness Forum.

May — Ottawa, Ontario

Daryl was in Ottawa raising awareness and talking to MPs about hep C, screening guidelines, and new advances in therapies that can now cure hep C.

July 9 — Richmond, British Columbia

PHCN held an Advocacy Training and Planning Day for hepatitis C advocates from around BC.

July 21 — Victoria, British Columbia

Daryl traveled to Victoria to meet with government officials. He left feeling that the day included some good discussions and was very worthwhile.

July 28 — Vancouver, British Columbia

Daryl was quoted by BC’s Ministry of Health about Holkira Pak.

July 28 — Vancouver, British Columbia

World Hepatitis Day 2015
Spoke at the Vancouver World Hepatitis Day event at Creekside Community Centre on False Creek. Dr Darryl Plecas, Parliamentary Secretary to the Minister of Health, also spoke at this event, indicating great awareness of viral hepatitis in BC.

September 2 – 4 — Glasgow, Scotland

World Hepatitis Summit 2015
Daryl attended the World Hepatitis Summit as a representative for Action Hepatitis Canada (AHC). In his AHC role, Daryl presented about AHC and World Hepatitis Day, hosted a lunch for Canadian summit delegates, and took part in a consultation hosted by the Medicines Patent Pool.

September — Present

HepatitisC.net
Daryl started writing for HepatitisC.net. His posts can be read online.

October 13 – 14 — Toronto, Ontario

Action Hepatitis Canada’s Advocacy Meeting
At the meeting Daryl and Cheryl Reitz, from HepC BC, spoke on hep C advocacy in BC.

October 20 — Windsor, England

Advocacy Meeting Sponsored by AbbVie
At this meeting, Daryl represented AHC. He may have been the only person representing those with hep C who has had the disease.

October 21 — Ottawa, Ontario, via webcam

Canadian Institutes of Health Research (CIHR) Lecture
Daryl was invited to speak to CIHR about advocacy as a member of CanHepC, a new group formed to address hep C issues in Canada.

November 11 – 12 — Vancouver, British Columbia

The 2nd International Hepatitis Cure & Eradication Conference
The meeting gathered hepatitis experts from different disciplines to learn how science can influence public policy to work to cure and eliminate hepatitis. Daryl was one of the meeting’s speakers.

December 4

The American Journal of Medicine (AJM)‘s exclusive hepatitis C interview with Daryl was published.

December 4

Daryl was featured in HCV New Drug Research‘s December newsletter.

Thank you Daryl and all of the hep C advocates who worked so hard in 2015 to speak up for those living with hep C!

Deb and Daryl, hep C advocates, at the 2nd International Hepatitis Cure & Eradication Conference, November 11 – 12, 2015.
Deb, PHCN’s Program Manager,  and Daryl at the 2nd International Hepatitis Cure & Eradication Conference, November 11 – 12, 2015. They are standing in the fourth row from the top. (Photo courtesy of the 2nd International Hepatitis Cure & Eradication Conference)

Hep C Advocacy Resources and the 2015 Election

Hep C AdvocacyWhile Canada’s political candidates have been working to get their voices heard, hep C advocates have also been campaigning, raising their voices for a better response to hep C in Canada. Some of those hepatitis C advocates have been helped by hep C advocacy election toolkits. The following are examples of advocacy toolkits geared towards the election but that include advocacy tools that can be useful after election day.

Hep C Advocacy Election Toolkits

Action Hepatitis Canada’s Election Toolkit 2015

Action Hepatitis Canada’s Election Toolkit 2015 includes:

  • The toolkit’s key message – “We now have a cure for hepatitis C, an illness that affects 250,000 Canadians and kills 1000 annually, and we have a public healthcare system that can deliver that cure to those who need it. It is time to work towards the elimination of hepatitis C in Canada.”
  • The toolkit’s key question – “How would your government work towards the elimination of hepatitis C in Canada?”
  • Social media images
  • Suggested tweetable messages
  • An editable letter template

CTAC and YouthCo’s Pan-Canadian PharmaCare Pre-Election Toolkit

CTAC and YouthCo’s Pan-Canadian PharmaCare Pre-Election Toolkit includes:

  • The toolkit’s key message – Canada needs a national drug plan
  • Lists of actions you can take before the federal election
  • Suggested tweetable messages and images
  • An editable letter template
  • Lists of organizations supporting pan-Canadian PharmaCare and other resources

CTAC Patient Input Group Webinar

ombitasvir/paritaprevir/ritonavirOn September 21 @ 8am PST / 11am EDT, the Canadian Treatment Action Council (CTAC) will be hosting a webinar about the upcoming hep C treatment AbbVie 2D – GT4 (ombitasvir / paritaprevir / ritonavir). The treatment is about to undergo a CADTH Common Drug Review (CDR), which is now collecting patient input.

The patient input survey that will follow CTAC’s webinar is different from PHCN’s patient input survey or PHCN’s loved ones / caregivers survey. Please consider filling out the PHCN survey that was created for you as well as CTAC’s survey.

Registration for the CTAC webinar is required
. Click here to register or for more information about the webinar.

About the Canadian Treatment Action Council (CTAC)

CTAC is a Canadian non-governmental organization led by and for people living with HIV and HIV/HCV co-infection. Since 1996, they have been working to secure and ensure equitable, affordable, and timely access to treatment and care and support for people in Canada living with HIV and HIV/HCV co-infection.